AIMS: Calcific aortic valve stenosis (CAS) is an active disease like atherosclerosis. Effect of diabetes (D) on severity of CAS is not well documented. METHODS AND RESULTS: We retrospectively analysed 166 consecutive patients with CAS and multiple echocardiograms from January 1997 to March 2005. Aortic valve area (AVA) was measured using the continuity equation. CAS severity was categorized using AVA. D and non-D patients were compared for differences in sex, hypertension, smoking, statin use using chi(2) tests. Comparisons between D and non-D for changes in AVA per year were performed using ANOVA. Study cohort included 166 males with age 70 +/- 9 years, of which 72 (43%) had D. Baseline CAS was mild in 66 subjects, moderate in 75, and severe in 25. D subjects smoked less (P = 0.02), but all other variables were similar (P > 0.05). The interaction between D and baseline CAS severity was significant (P = 0.0191), indicating comparisons should be viewed by baseline CAS severity. D had significantly larger change in AVA than non-D (P = 0.0016) for those with moderate CAS at baseline only. Adjusting for statin use did not alter the results. CONCLUSION: CAS severity progresses faster in D than in non-D in subjects with moderate CAS at baseline. Statins do not affect progression of CAS.
AIMS: Calcific aortic valve stenosis (CAS) is an active disease like atherosclerosis. Effect of diabetes (D) on severity of CAS is not well documented. METHODS AND RESULTS: We retrospectively analysed 166 consecutive patients with CAS and multiple echocardiograms from January 1997 to March 2005. Aortic valve area (AVA) was measured using the continuity equation. CAS severity was categorized using AVA. D and non-D patients were compared for differences in sex, hypertension, smoking, statin use using chi(2) tests. Comparisons between D and non-D for changes in AVA per year were performed using ANOVA. Study cohort included 166 males with age 70 +/- 9 years, of which 72 (43%) had D. Baseline CAS was mild in 66 subjects, moderate in 75, and severe in 25. D subjects smoked less (P = 0.02), but all other variables were similar (P > 0.05). The interaction between D and baseline CAS severity was significant (P = 0.0191), indicating comparisons should be viewed by baseline CAS severity. D had significantly larger change in AVA than non-D (P = 0.0016) for those with moderate CAS at baseline only. Adjusting for statin use did not alter the results. CONCLUSION:CAS severity progresses faster in D than in non-D in subjects with moderate CAS at baseline. Statins do not affect progression of CAS.
Authors: Andrea Sonaglioni; Gian Luigi Nicolosi; Elisabetta Rigamonti; Michele Lombardo Journal: Int J Cardiovasc Imaging Date: 2021-02-05 Impact factor: 2.357
Authors: Brian R Lindman; Suzanne V Arnold; José A Madrazo; Alan Zajarias; Stephanie N Johnson; Julio E Pérez; Douglas L Mann Journal: Circ Heart Fail Date: 2011-02-25 Impact factor: 8.790
Authors: Giovanni Pulignano; Michele Massimo Gulizia; Samuele Baldasseroni; Francesco Bedogni; Giovanni Cioffi; Ciro Indolfi; Francesco Romeo; Adriano Murrone; Francesco Musumeci; Alessandro Parolari; Leonardo Patanè; Paolo Giuseppe Pino; Annalisa Mongiardo; Carmen Spaccarotella; Roberto Di Bartolomeo; Giuseppe Musumeci Journal: Eur Heart J Suppl Date: 2017-05-02 Impact factor: 1.803
Authors: Morten Sengeløv; Susan Cheng; Tor Biering-Sørensen; Kunihiro Matsushita; Suma Konety; Scott D Solomon; Aaron R Folsom; Amil M Shah Journal: J Am Heart Assoc Date: 2018-02-03 Impact factor: 5.501